Chiropractor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Todjide Evans

Chiropractor Jefferson, GA Chiropractor

NPI 1487841896 CMS profile 1032263

22 South Public Square, Jefferson, GA 30549

Open in the dashboard

General payments

$274

20 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Todjide Evans of Jefferson, GA is reported in the CMS Open Payments database as having received $274 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Chiropractor profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $16 1
2020 General $41 3
2019 General $216 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todjide Evans
  • Chiropractor median
  • Middle half of Chiropractor
  • National median

In program year 2025, general payments to Todjide Evans were reported at $0. Among 1,761 Chiropractor profiles paid that year, the median was $41 and the middle half received between $22 and $119.

Show as a table
Year Todjide Evans Chiropractor median Middle half National median
2019 $216 $51 $18–$114 $163
2020 $41 $31 $17–$81 $114
2021 $16 $38 $19–$119 $132
2022 $0 $47 $21–$122 $149
2023 $0 $41 $21–$125 $160
2024 $0 $41 $21–$124 $164
2025 $0 $41 $22–$119 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $274 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $274 20 payments
Products named General payments · program years 2019–2021
  1. RELISTOR Gastroenterology $274 20 payments
  2. RELISTOR Gastroenterology $199 15 payments
  3. LUCEMYRA $172 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record